EP2655663A4 - Biomarkers and uses thereof in prognosis and treatment strategies for right-side colon cancer disease and left-side colon cancer disease - Google Patents
Biomarkers and uses thereof in prognosis and treatment strategies for right-side colon cancer disease and left-side colon cancer diseaseInfo
- Publication number
- EP2655663A4 EP2655663A4 EP11850360.6A EP11850360A EP2655663A4 EP 2655663 A4 EP2655663 A4 EP 2655663A4 EP 11850360 A EP11850360 A EP 11850360A EP 2655663 A4 EP2655663 A4 EP 2655663A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- colon cancer
- cancer disease
- side colon
- biomarkers
- prognosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y106/00—Oxidoreductases acting on NADH or NADPH (1.6)
- C12Y106/03—Oxidoreductases acting on NADH or NADPH (1.6) with oxygen as acceptor (1.6.3)
- C12Y106/03001—NAD(P)H oxidase (1.6.3.1), i.e. NOX1
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/54—Determining the risk of relapse
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201061459864P | 2010-12-20 | 2010-12-20 | |
PCT/US2011/066233 WO2012088146A2 (en) | 2010-12-20 | 2011-12-20 | Biomarkers and uses thereof in prognosis and treatment strategies for right-side colon cancer disease and left-side colon cancer disease |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2655663A2 EP2655663A2 (en) | 2013-10-30 |
EP2655663A4 true EP2655663A4 (en) | 2015-01-28 |
Family
ID=46314850
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP11850360.6A Withdrawn EP2655663A4 (en) | 2010-12-20 | 2011-12-20 | Biomarkers and uses thereof in prognosis and treatment strategies for right-side colon cancer disease and left-side colon cancer disease |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP2655663A4 (en) |
WO (1) | WO2012088146A2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2821507A1 (en) * | 2013-07-01 | 2015-01-07 | Centre National de la Recherche Scientifique (CNRS) | A method for detecting, identifying and/or quantifying a pathogen in an individual |
CN114540499A (en) * | 2022-03-17 | 2022-05-27 | 郑州源创吉因实业有限公司 | Application of model constructed based on PCD related gene combination in preparation of product for predicting colon adenocarcinoma prognosis |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1355149A2 (en) * | 2002-03-29 | 2003-10-22 | Ortho-Clinical Diagnostics, Inc. | Assessing colorectal cancer |
WO2005010486A2 (en) * | 2003-07-18 | 2005-02-03 | Lee Nancy M | Biomarker panel for colorectal cancer |
WO2010132817A1 (en) * | 2009-05-14 | 2010-11-18 | Cancer Prevention Pharmaceuticals, Llc | Carcinoma diagnosis and treatments, based on odc1 genotype |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2919061B1 (en) * | 2007-07-19 | 2009-10-02 | Biomerieux Sa | METHOD OF DOSING PLASTINE-I FOR IN VITRO DIAGNOSIS OF COLORECTAL CANCER. |
-
2011
- 2011-12-20 EP EP11850360.6A patent/EP2655663A4/en not_active Withdrawn
- 2011-12-20 WO PCT/US2011/066233 patent/WO2012088146A2/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1355149A2 (en) * | 2002-03-29 | 2003-10-22 | Ortho-Clinical Diagnostics, Inc. | Assessing colorectal cancer |
WO2005010486A2 (en) * | 2003-07-18 | 2005-02-03 | Lee Nancy M | Biomarker panel for colorectal cancer |
WO2010132817A1 (en) * | 2009-05-14 | 2010-11-18 | Cancer Prevention Pharmaceuticals, Llc | Carcinoma diagnosis and treatments, based on odc1 genotype |
Non-Patent Citations (1)
Title |
---|
See also references of WO2012088146A2 * |
Also Published As
Publication number | Publication date |
---|---|
WO2012088146A2 (en) | 2012-06-28 |
EP2655663A2 (en) | 2013-10-30 |
WO2012088146A3 (en) | 2012-10-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG2014007454A (en) | Pancreatic cancer biomarkers and uses thereof | |
IL252163A0 (en) | Lung cancer biomarkers and uses thereof | |
IL223295A0 (en) | Lung cancer biomarkers and uses thereof | |
IL222234A0 (en) | Biomarkers for mdm2 inhibitors for use in treating disease | |
EP2382331A4 (en) | Cancer biomarkers | |
PL2653546T3 (en) | Marker for predicting stomach cancer prognosis and method for predicting stomach cancer prognosis | |
EP2536854A4 (en) | Personalized tumor biomarkers | |
HK1175476A1 (en) | Cancer treatment | |
ZA201207574B (en) | Phytocannabinoids in the treatment of cancer | |
GB0906458D0 (en) | Macromolecules for diagnosis and prognosis | |
HK1206414A1 (en) | Biomarkers for gastric cancer and uses thereof | |
GB0922085D0 (en) | Cancer diagnosis and treatment | |
HK1143157A1 (en) | 4-pyridinone compounds and their use for cancer 4- | |
EP2457092A4 (en) | Cancer biomarker and the use thereof | |
IL222958A0 (en) | Cancer treatment | |
HK1247207A1 (en) | New compounds for treating cancer and other disease | |
EP2630498A4 (en) | Prognostic biomarkers in patients with ovarian cancer | |
GB0901837D0 (en) | Cancer diagnosis and treatment | |
EP2655663A4 (en) | Biomarkers and uses thereof in prognosis and treatment strategies for right-side colon cancer disease and left-side colon cancer disease | |
EP2223117A4 (en) | Breast cancer treatment and treatment prediction | |
EP2709730A4 (en) | Treatment and prognosis of cancer | |
TWI563256B (en) | Marker for colon cancer and method for detecting colon cancer | |
EP2403963A4 (en) | A biomarker and treatment for cancer | |
EP2612861A4 (en) | Fluorinated thiazoles for use in treating cancer | |
EP2721410A4 (en) | Biomarkers for epithelial cancer diagnosis and treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20130722 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20150107 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: G01N 33/574 20060101ALI20141219BHEP Ipc: C12N 15/113 20100101ALI20141219BHEP Ipc: C12N 15/11 20060101ALI20141219BHEP Ipc: C12Q 1/68 20060101AFI20141219BHEP |
|
17Q | First examination report despatched |
Effective date: 20150915 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20190103 |